Retatrutide and Vitamin B12: Interaction Guide

Retatrutide vitamin B12 interaction and supplementation is a question that arises because retatrutide, an investigational triple hormone receptor agonist developed by Eli Lilly, slows gastric emptying in a way that could theoretically affect how the body processes B12. Retatrutide has no UK marketing authorisation and is accessible only within authorised clinical trials. This article outlines what published trial data do and do not report about nutritional deficiencies, who may be at greater risk of low B12, how to recognise deficiency symptoms, and how supplementation decisions should be approached under clinical guidance.

What Is Retatrutide and Where Does It Stand with UK Regulators?

Retatrutide has no UK marketing authorisation and can only be accessed within an authorised clinical trial. The MHRA has not evaluated it for routine clinical use, and no regulatory review has concluded.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be accessed only within an authorised clinical trial.^[1] It is an investigational medicine developed by Eli Lilly that acts simultaneously on three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple agonist mechanism distinguishes it pharmacologically from currently licensed GLP-1 receptor agonists, though no head-to-head trials with licensed treatments have been conducted.

Because retatrutide has no UK marketing authorisation, the Medicines and Healthcare products Regulatory Agency (MHRA) has not evaluated it for routine clinical use, and no date for a potential application can be given. Anyone who encounters a website or online pharmacy claiming to sell retatrutide outside a clinical trial should be aware that such a product would not be a licensed medicine and may be falsified or unsafe.

For people interested in licensed weight-management treatments, options do exist and can be discussed with a GP. The clinical research programme for retatrutide, including the TRIUMPH and TRANSCEND trial series, has progressed to Phase 3, and initial results from some arms (including TRANSCEND-T2D-1) have been reported at major congresses and in peer-reviewed publications.^[2][4] However, the full dataset across all trial arms has not yet been published, and no regulatory review has concluded. Until a marketing authorisation is granted, retatrutide remains a research medicine only.

Could retatrutide affect how your body absorbs vitamin B12?

No confirmed interaction between retatrutide and vitamin B12 absorption has been published, but slowed gastric emptying may theoretically affect B12 processing. This remains a theoretical concern rather than an established finding.

There is no established, confirmed interaction between retatrutide and vitamin B12 absorption documented in published trial data to date, but the question is scientifically reasonable given what is known about the drug class. Retatrutide slows gastric emptying, a pharmacological effect shared with other GLP-1 receptor agonists.^[3] Slower gastric emptying increases the time that food spends in the stomach, which may in principle affect the early stages of B12 processing: gastric acid and pepsin are needed to release protein-bound B12 from food, after which B12 initially binds to haptocorrin (a salivary protein).^[7][8] Intrinsic factor, produced by parietal cells in the stomach lining, binds to free B12 primarily in the duodenum after haptocorrin is digested by pancreatic enzymes, and the resulting complex is then absorbed at specialised receptors in the terminal ileum.^[7][8] The clinical significance of any effect that altered gastric function might have on this multi-step process, specifically with retatrutide, has not been quantified in published research.

It is also worth noting that retatrutide's glucagon receptor agonism adds a metabolic dimension not present in dual or single agonists, and the full nutritional consequences of this mechanism are still being characterised in ongoing trials. Until more data are available, the possibility of an effect on B12 absorption should be considered a theoretical concern rather than a confirmed finding, and any monitoring decisions should be guided by a clinician familiar with the trial protocol.

What do clinical trials report about retatrutide and nutritional deficiencies?

Published Phase 2 and initial Phase 3 trial data have not reported vitamin B12 status as a primary or secondary endpoint. The absence of data does not confirm safety; it reflects the focus of early-phase trial design.

Published Phase 2 trial data for retatrutide, reported in the New England Journal of Medicine in 2023, focused primarily on weight reduction, glycaemic outcomes and safety signals such as gastrointestinal adverse effects, but did not report detailed findings on micronutrient status including vitamin B12.^[4] Initial Phase 3 results from the TRANSCEND trial series have since been reported, though full results across all arms and populations are not yet available in peer-reviewed form, and no published Phase 3 report has specifically characterised B12 status as a primary or secondary endpoint.

This absence of published data on B12 specifically does not mean no effect exists. It reflects the fact that nutritional biomarkers are not always primary or secondary endpoints in early-phase trials, and that longer follow-up periods are typically needed before deficiencies become clinically apparent. Participants in these trials are monitored under strict protocols, and any emerging nutritional signals would be captured and reported through those channels.

For context, the UK Summaries of Product Characteristics for licensed GLP-1 receptor agonists including semaglutide (Wegovy, Ozempic) and liraglutide (Saxenda) do not list vitamin B12 deficiency as a recognised adverse effect.^[10][11] Retatrutide's trial populations are subject to similar dietary changes associated with significant caloric restriction, which may compound any pharmacological effect on nutrient absorption, though this remains a theoretical consideration in the absence of direct evidence for retatrutide specifically.

Who is most at risk of low B12 levels during GLP-1 based treatments?

People with pre-existing risk factors, including older adults, those on vegan diets, metformin users, and individuals with gastrointestinal surgery history or pernicious anaemia, are at greatest risk of clinically significant B12 deficiency.

People with pre-existing risk factors for vitamin B12 deficiency are most likely to experience clinically significant low B12 levels during treatment with any GLP-1 based medicine, including investigational agents such as retatrutide. The following groups warrant particular attention:

• Older adults, in whom gastric acid production naturally declines with age, reducing the release of protein-bound B12 from food

• People following a vegan or strict vegetarian diet, since B12 is found almost exclusively in animal-derived foods

• Those taking metformin, which is commonly used in type 2 diabetes and is associated with reduced B12 absorption through a mechanism involving calcium-dependent membrane action in the ileum^[13][14]

• People taking long-term proton pump inhibitors or H2-receptor antagonists, which reduce gastric acid secretion and may impair the release of protein-bound B12 from food^[16][17]

• People with a history of gastrointestinal surgery, including bariatric procedures, which may reduce intrinsic factor production or ileal absorptive capacity

• Individuals with autoimmune gastritis or pernicious anaemia, in whom intrinsic factor is absent or severely reduced

• Those with inflammatory bowel disease affecting the terminal ileum, where B12 absorption takes place

When GLP-1 based treatment is combined with significant caloric restriction, as is common in weight-management programmes, dietary intake of B12 may also fall. This dietary reduction, layered on top of any pharmacological effect on gastric function, can accelerate the depletion of B12 stores in people who are already borderline deficient. A clinician involved in a retatrutide trial should be informed of any of these risk factors so that appropriate monitoring can be arranged under the study protocol.

Signs of vitamin B12 deficiency you should not ignore

Key signs include fatigue, tingling or numbness in the hands or feet, balance problems, cognitive changes and glossitis. Neurological symptoms should prompt same-day GP assessment, as severe deficiency can cause irreversible nerve damage.

Vitamin B12 deficiency can develop gradually over months to years because the liver stores enough B12 to last for a prolonged period, meaning symptoms may not appear until stores are substantially depleted.^[28] Recognising the signs early is important because neurological damage caused by severe or prolonged deficiency can be irreversible.^[19][20]

Common symptoms include:

• Fatigue and weakness, which are non-specific but among the earliest features

• Tingling, numbness or a pins-and-needles sensation in the hands or feet, reflecting peripheral nerve involvement

• Difficulty walking or balance problems, which may indicate subacute combined degeneration of the spinal cord in more advanced cases

• Cognitive changes, including difficulty concentrating, memory problems or low mood

• A sore, smooth or inflamed tongue (glossitis)

• Pale or slightly yellow skin, resulting from the haemolytic component of megaloblastic anaemia

• Mouth ulcers and general oral discomfort

New or worsening neurological symptoms, such as progressive tingling, gait disturbance or balance problems, should prompt same-day assessment by a GP or urgent care service rather than waiting for a scheduled appointment.

If you are participating in a clinical trial involving retatrutide and notice any of these symptoms, you should report them promptly to the trial team under the study protocol. For symptoms that are severe, rapidly worsening or accompanied by chest pain or breathing difficulty, call 999 or go to the nearest accident and emergency department. For non-urgent concerns that cannot wait for a scheduled trial visit, NHS 111 can provide guidance, and your GP remains the appropriate contact for ongoing health concerns outside the trial setting. Suspected side effects of a medicine you are taking outside a clinical trial can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk; if you are enrolled in a trial, report through the study team or sponsor as directed by the trial protocol.

Should you take a B12 supplement alongside weight-loss injections?

Supplementation should only be decided with a healthcare professional after baseline B12 levels are assessed. Trial participants must discuss any supplementation with the trial team, as unsanctioned supplements may affect study outcomes.

Whether to take a vitamin B12 supplement alongside any weight-loss injection, including investigational medicines such as retatrutide or licensed treatments, is a decision that should be made with a healthcare professional rather than on a self-directed basis. There is currently no UK clinical guideline, NICE recommendation or published retatrutide trial protocol that mandates routine B12 supplementation for all people using GLP-1 based treatments. Supplementing without establishing baseline levels and identifying a genuine deficiency or high-risk profile may mask symptoms without addressing an underlying cause.

For people participating in a retatrutide clinical trial, any decision about supplementation must be discussed with the trial team, as unsanctioned supplements can affect trial outcomes and may interact with the study protocol. Outside a trial, people using licensed weight-management medicines who are concerned about B12 status should ask their GP for a blood test. A GP will typically assess a full blood count and serum B12 and folate levels; where results are borderline, further tests such as methylmalonic acid or homocysteine may be considered in line with NICE and British Society for Haematology guidance.^[25] If a deficiency is confirmed, treatment will depend on its severity and cause: oral cyanocobalamin supplements are appropriate for dietary deficiency, while intramuscular hydroxocobalamin injections are used when absorption is impaired.^[25][26]

Practical steps that support adequate B12 intake during any weight-management programme include maintaining dietary sources such as meat, fish, eggs and dairy where these are not excluded, and discussing fortified foods with a registered dietitian if animal products are avoided. Pregnancy and breastfeeding are exclusion criteria for retatrutide trials, and women of childbearing potential participating in trials are required to use effective contraception. Anyone who becomes pregnant during a trial should inform the trial team immediately. For broader nutritional support during weight management, a referral to a dietitian through your GP is the appropriate route.

Frequently Asked Questions